Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals.
about
Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical RelevanceAssessing the Immunogenicity of BiopharmaceuticalsBiologics in organ transplantationCharacterizing biological products and assessing comparability following manufacturing changes.Evaluating real-time immunohistochemistry on multiple tissue samples, multiple targets and multiple antibody labeling methods.Current methods for detecting antibodies against erythropoietin and other recombinant proteins.Prevalence and isotypic complexity of the anti-Chinese hamster ovary host cell protein antibodies in normal human serumRepeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity.Unwanted immunogenicity: lessons learned and future challenges.Development and optimization of neutralizing antibody assays to monitor clinical immunogenicity.Preclinical development of therapeutic biologics.Biologic agents in islet transplantation.Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantationAssays and strategies for immunogenicity assessment of biological agents.Assessment of the immunogenicity of gonadotrophins during controlled ovarian stimulation.Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment.Safety and efficacy of thrombin-JMI: a multidisciplinary expert group consensus.Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates.Multiplexed serum measurement of IgG, IgA, IgM, and IgE antibody responses to therapeutic biologicals.Label-Free Quantification of Anti-TNF-α in Patients Treated with Adalimumab Using an Optical Biosensor.
P2860
Q26747193-1ACF8D06-E10B-4EF3-B260-9D4733E7C67DQ26751485-80770375-F56A-4990-AEC4-7F7CD0B91C42Q26829578-BB1DDD03-56F9-4A84-BE9D-ABBC6D424456Q30344134-0A4707C7-9CC2-4448-8851-E55C9B3AF4EBQ31146406-43E60DD7-47A5-4D76-9DDC-A307C51AC100Q33593537-EEA1E01A-17E3-41E4-8EEB-9F4481D479F9Q33611522-8BD5DD0B-AD3D-42DC-AB59-DD37A8772578Q35108282-27CE95D0-2C0E-4C8D-8C23-94307050C395Q37810215-BDA0F784-F220-44A9-82B5-221A30E58618Q38064917-80F72DF7-0A9C-4DC2-967D-82047C56703CQ38088310-FD2265D2-43A7-4318-B87D-460CF258C628Q38126884-E192F769-B005-4BE8-B8CC-D3A7699D40C1Q38186025-D1998DCB-C5DB-4257-A0E4-0B763670755AQ38266318-384B365D-787E-4C4F-A17B-6E3094137E4CQ38288448-8F7CBCA8-D0B8-4A48-BAF5-B6F1C0614531Q38822920-7D7436E1-8403-4978-8374-64FAFD26A3B0Q43888363-81BEA817-0158-42C0-BB57-9C2BD82880F6Q46070437-AC5D11CE-E923-4125-9B5F-1CF8D66FD864Q51021473-56F7D886-38E7-4591-89C8-75038329F69AQ51451769-D2B63E67-28E9-416B-A687-C0380D9FC102Q55259703-622B167A-4B41-4BC3-801B-6968B719D8CE
P2860
Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Strategies for detection, meas ...... ed by therapeutic biologicals.
@ast
Strategies for detection, meas ...... ed by therapeutic biologicals.
@en
type
label
Strategies for detection, meas ...... ed by therapeutic biologicals.
@ast
Strategies for detection, meas ...... ed by therapeutic biologicals.
@en
prefLabel
Strategies for detection, meas ...... ed by therapeutic biologicals.
@ast
Strategies for detection, meas ...... ed by therapeutic biologicals.
@en
P2093
P1476
Strategies for detection, meas ...... ed by therapeutic biologicals.
@en
P2093
P356
10.1016/S0022-1759(03)00206-0
P577
2003-07-01T00:00:00Z